SETD2 and nonpapillary renal cell carcinoma: Molecular features of this cohort were typical of ccRCC (Ricketts et al., 2018; Turajlic et al., 2018b), including mutations in VHL (77%), VHL methylation in an additional 15%, PBRM1 (62%), SETD2 (38%), BAP1 (15%), and KDM5C (38%), with both clonal and subclonal alterations detected (Figure 1B).